GlassScriptPhysician profile
Paul Marino
NPI 1104903871
$3,454.27
in general payments reported to CMS, 2019-2025
11 companies · $108 in 2025
The $108 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.97 · 2022: $1,069 · 2023: $1,875 · 2024: $390 · 2025: $108.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,736 · Travel and Lodging: $621 · Gift: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,735.56 |
| Travel and Lodging | $620.54 |
| Gift | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,899.83 | 2021-2023 | Da Vinci Surgical System |
| Enterra Medical, INC. | $897.86 | 2023-2024 | |
| Davol INC. | $305.76 | 2023-2025 | Phasix Mesh, Arista |
| Medtronic, INC. | $163.06 | 2022 | |
| Ethicon US, LLC | $40.65 | 2023 | Echelon Endopath |
| Innovation Technologies INC | $30.70 | 2023 | Irrisept |
| Tela Bio, INC. | $28.90 | 2024 | Ovitex 2s |
| Argenx US, INC. | $28.44 | 2025 | Vyvgart Hytrulo |
| Biogen, INC. | $23.86 | 2024 | Tysabri, Vumerity |
| Integra Lifesciences Corporation | $18.21 | 2023 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Abbvie INC. | $17.00 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Marino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.